文献速递妇科肿瘤

在晚期和转移性子宫内膜癌一线治疗中加入免疫治疗

Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer.
PubMed 文献 · Ann Oncol · 2024-02-29

本文对4项III期试验(RUBY、NRG-GY018、AtTEnd、DUO-E)进行综述与Meta分析,共2320例晚期或复发性子宫内膜癌患者。汇总数据显示化疗联合免疫治疗较单纯化疗显著改善无进展生存(HR 0.70,95%CI 0.62-0.79)和总生存(HR 0.75,95%CI 0.63-0.89),其中错配修复缺陷/微卫星高度不稳定(MMRd/MSI-H)亚组无进展生存获益更显著(n=563;HR 0.33,95%CI 0.23-0.43)。

要点

  • 化疗联合免疫治疗较单纯化疗改善全部患者无进展生存(HR 0.70,95%CI 0.62-0.79)。
  • MMRd/MSI-H亚组无进展生存获益更显著(n=563;HR 0.33,95%CI 0.23-0.43)。
  • 全部患者总生存改善(HR 0.75,95%CI 0.63-0.89),但总生存数据成熟度仍低。

核心结论

  • 在晚期和转移性子宫内膜癌初始治疗中加入免疫治疗可大幅改善肿瘤学结局,尤其在MMRd/MSI-H亚组。
  • 该特定亚组目前是评估无化疗方案潜力的研究焦点。
  • 正在进行的探索性分析旨在识别适合纳入临床试验的无应答患者。

研究设计与样本

  • 本文是对研究免疫治疗在晚期或复发性子宫内膜癌一线治疗中作用的III期试验进行的综述与Meta分析。
  • 汇总数据来自4项试验(RUBY、NRG-GY018、AtTEnd、DUO-E)共2320例患者。

主要发现

  • 全部患者中,化疗联合免疫治疗较单纯化疗显著改善无进展生存(HR 0.70,95%CI 0.62-0.79)。
  • MMRd/MSI-H肿瘤患者无进展生存获益更显著(n=563;HR 0.33,95%CI 0.23-0.43)。
  • 错配修复正常/微卫星稳定组无进展生存获益虽较弱但仍持续存在(n=1757;HR 0.74,95%CI 0.60-0.91)。
  • 全部患者中,化疗联合免疫治疗较单纯化疗改善总生存(HR 0.75,95%CI 0.63-0.89),但总生存数据成熟度仍低。

局限性

  • 总生存数据成熟度仍低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunotherapy has transformed the endometrial cancer treatment landscape, particularly for those exhibiting mismatch repair deficiency [MMRd/microsatellite instability-hypermutated (MSI-H)]. A growing body of evidence supports the integration of immunotherapy with chemotherapy as a first-line treatment strategy. Recently, findings from ongoing trials such as RUBY (NCT03981796), NRG-GY018 (NCT03914612), AtTEnd (NCT03603184), and DUO-E (NCT04269200) have been disclosed. MATERIALS AND METHODS: This paper constitutes a review and meta-analysis of phase III trials investigating the role of immunotherapy in the first-line setting for advanced or recurrent endometrial cancer. RESULTS: The pooled data from 2320 patients across these trials substantiate the adoption of chemotherapy alongside immunotherapy, revealing a significant improvement in progression-free survival compared to chemotherapy alone [hazard ratio (HR) 0.70, 95% confidence interval (CI) 0.62-0.79] across all patient groups. Progression-free survival benefits are more pronounced in MMRd/MSI-H tumors (n = 563; HR 0.33, 95% CI 0.23-0.43). This benefit, albeit less robust, persists in the MMR-proficient/microsatellite stable group (n = 1757; HR 0.74, 95% CI 0.60-0.91). Pooled data further indicate that chemotherapy plus immunotherapy enhances overall survival compared to chemotherapy alone in all patients (HR 0.75, 95% CI 0.63-0.89). However, overall survival data maturity remains low. CONCLUSIONS: The incorporation of immunotherapy into the initial treatment for advanced and metastatic endometrial cancer brings about a substantial improvement in oncologic outcomes, especially within the MMRd/MSI-H subset. This specific subgroup is currently a focal point of investigation for evaluating the potential of chemotherapy-free regimens. Ongoing exploratory analyses aim to identify non-responding patients eligible for inclusion in clinical trials.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Bogani G, Monk BJ, Powell MA, et al. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer. Ann Oncol. 2024. PMID: 38431043. doi:10.1016/j.annonc.2024.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。